Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease

What Was Tested

This observational study looks at Somatostatin and Vasopressin.

Somatostatin (SST) inhibits intracellular cyclic adenosine monophosphate (cAMP) production and thus may modify cyst formation in autosomal dominant polycystic kidney disease (ADPKD).

Who Took Part

According to the abstract, 127 patients were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

In this observational study, fasting concentrations of SST were measured in 127 ADPKD patients (diagnosed upon the revised Ravine criteria) by ELISA. cAMP was measured in 24 h urine by Radio Immuno Assay.

Additionally, baseline versus follow-up SST concentrations were compared in ADPKD patients during vasopressin V2 receptor antagonist (tolvaptan) (n = 27) or SST analogue (lanreotide) treatment (n = 25).

How the Study Was Run

Kidney function was measured (mGFR) as 125I-iothalamate clearance, and total kidney volume was measured by MRI volumetry and adjusted for height (htTKV).

Disease progression was expressed as annual change in mGFR and htTKV.

What Was Measured

The subject headings attached to it are Antidiuretic Hormone Receptor Antagonists, Antineoplastic Agents, Cyclic AMP, Disease Progression, Fasting, Glomerular Filtration Rate and Kidney.

The authors tagged it with the keywords ADPKD, Biomarker, Somatostatin and cAMP.

What This Means in Plain Language

This is an observational study of Somatostatin and Vasopressin in 127 patients.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (BMC nephrology), a journal based in England.

More context: the Somatostatin compound page and the Vasopressin compound page, all human trials.